We invest in ideas and commercialise results
We take commercially promising research and build companies that enterprise and innovate, creating positive societal, economic and environmental change.
We offer a combination of expertise, skills and facilities to help our spinouts succeed, and connect companies with funding networks and guide them in protecting and enhancing intellectual property.
Stuart Mills, CEO, STAR-Dundee
Professor Andrew Hopkins, Chief Executive, Exscientia
Read about some of our success stories...
Developing drugs using ground-breaking targeted protein degradation technology from the laboratory of Professor Alessio Ciulli. It is backed by Advent Life Sciences, one of the leading trans-Atlantic venture capital investors.
Developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.
DC Biosciences Ltd
DC Biosciences Ltd provides pharmaceutical and biotech companies with proteomics services to accelerate the development of safer drugs.
Glencoe Software Ltd
Design and production of software and data storage solutions for biological imaging. Glencoe Software is the commercial arm of the Open Microscopy Environment, a community-led, open source data specification and software development consortium.
Specialises in the discovery of drugs, which are safe and effective, for the treatment of skin diseases including eczema, non-melanoma skin cancers and orphan skin diseases.
Developing powerful new software solutions for managing complex informatics and multidimensional proteomics scientific datasets in a wide range of laboratory and industrial environments.
Ten Bio Ltd
Advancing in vitro science by providing advanced ex vivo human skin models that closely mimic intact living skin. Their technology offers users a reliable alternative to animal testing and thus a more ethical and economic route to market.
Enables and supports ubiquitin system focused drug discovery by developing novel compounds targeted towards ubiquitin system proteins as well providing access to a suite of comprehensive research services and reagents.